Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Changes in M-spike and FLC and the risk of progression in SMM

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of an analysis that looked at dynamic changes in M-spike and free light chains (FLC) in patients with smoldering multiple myeloma (SMM). Patients with SMM have a varying risk of progression to multiple myeloma (MM), and the current risk scoring system is based solely on disease burden upon diagnosis. The analysis looked at baseline levels of M-spike and FLC over a year in nearly 400 SMM patients. The analysis confirmed that patients in the highest baseline quintile had a very high risk of progression, but also showed that patients with a large M-spike change or large increase in the FLC ratio over the first year had a very high risk of progression. Dr Hultcrantz highlights the importance of considering dynamic changes in these biomarkers when assessing risk of progression from SMM to MM. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


GSK Abbvie Amgen BMS